Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Walaa Fikry Elbossaty

Walaa Fikry Elbossaty

Damietta University, Damietta, Egypt

Title: Cluster of differentiations as biomarker in differentiation between ALL and AML

Biography

Biography: Walaa Fikry Elbossaty

Abstract

Introduction & Aim: Antigen surface markers represent as the new prognostic tool for detection of acute leukemia. To aim of this study is to investigate the prevalence expression of lymphoid and myeloid antigen lineage in acute leukemias.

Material & Methods: This study included 100 acute leukemias patients. Specimens were selected from consecutive patients who had sufficient material available. Among the 100 patients in which a detailed history, hematological, clinical and immunophenotyping analysis were performed. This study showed distribution of immunophenotyping characters between studied AML and ALL cases.

Results: The most abundant immunophenotyping features in acute myeloid leukemia were cMPO, CD33, CD117, CD13, CD14 and CD64, while the most abundant immunophenotyping features in acute lymphoblastic leukemia were CD19, CD79a, TdT, CD20, CD10 and CD34.

Conclusion: cMPO which act as independent prognostic factor for AML, CD10 and TdT can be used as independent prognostic factor to differentiate between ALL and AML.